How should I manage a patient with ferritin 60 ng/mL, transferrin saturation 21 %, total iron‑binding capacity 398 µg/dL, who has been on oral ferrous sulfate for 14 months and now has a recent small gastrointestinal bleed?

Management of Persistent Iron Deficiency with Recent GI Bleeding

This patient requires immediate bidirectional endoscopy to identify the source of GI bleeding, and should be transitioned to intravenous iron therapy given the failure of 14 months of oral supplementation and recent bleeding episode. 1

Current Iron Status Assessment

Your patient demonstrates persistent absolute iron deficiency despite prolonged oral therapy:

• Ferritin 60 ng/mL is below the optimal repletion target of 100 ng/mL for most conditions 2, 3
• Transferrin saturation 21% is marginally above the 20% threshold that defines iron deficiency, but remains suboptimal 2, 4
• TIBC 398 µg/dL is elevated, consistent with ongoing iron deficiency 2

The combination of these values after 14 months of oral ferrous sulfate indicates either inadequate absorption, ongoing blood loss exceeding replacement, or both 4.

Immediate Gastrointestinal Evaluation

The AGA strongly recommends bidirectional endoscopy (both EGD and colonoscopy) in the same setting for all asymptomatic postmenopausal women and men with iron deficiency anemia 1. This recommendation applies even more urgently to your patient given the recent small GI bleed, which represents a clear indication for endoscopic evaluation regardless of iron parameters 1.

Key Points About Endoscopy:

• Should be performed before assuming the recent bleed explains all iron deficiency 1
• Must evaluate both upper and lower GI tract simultaneously 1
• The goal is identifying treatable lesions (ulcers, angiodysplasia, polyps, malignancy) that may require specific intervention beyond iron replacement 1

Transition to Intravenous Iron

Intravenous iron is specifically indicated for patients with ongoing blood loss 4. Your patient meets multiple criteria for IV iron:

Indications Present:

• Ongoing blood loss (recent GI bleed) 4
• Failure of oral therapy after 14 months of treatment 4
• Likely impaired absorption given inadequate response to prolonged oral supplementation 4

IV Iron Formulation Options:

• Ferric derisomaltose (FDI) allows total dose infusion up to 1000-1500 mg in a single session, diluted in 100 mL normal saline over 20-30 minutes 2
• Ferric carboxymaltose (FCM) is another option for total dose infusion 2
• These formulations are preferred over iron sucrose for their ability to deliver larger doses in fewer infusions 2

Treatment Targets and Monitoring

Target Iron Parameters:

• Ferritin goal: ≥100 ng/mL in the absence of inflammation 2, 3
• Transferrin saturation goal: ≥20% (ideally higher) 2, 3
• Hemoglobin should increase 1-2 g/dL within 4-8 weeks of IV iron 2

Monitoring Schedule:

• Do NOT check iron parameters within 4 weeks of total dose infusion, as circulating iron interferes with assays 2
• Recheck CBC and iron studies (ferritin, TSAT) at 4-8 weeks post-infusion 2
• Hemoglobin should begin rising within 1-2 weeks 2

Common Pitfalls to Avoid

• Do not continue oral iron alone in the setting of ongoing GI blood loss—absorption cannot keep pace with losses 4
• Do not delay endoscopy while attempting further oral iron therapy—the recent bleed mandates evaluation 1
• Do not check ferritin immediately after IV iron—wait the full 4 weeks to avoid falsely elevated results 2
• Do not assume the recent small bleed fully explains 14 months of treatment failure—there may be an undiagnosed chronic source requiring identification 1

Ongoing Management Strategy

After initial IV iron repletion and endoscopic evaluation:

• If a treatable lesion is found and corrected, a single total dose infusion may suffice 2
• If ongoing losses continue (angiodysplasia, inflammatory lesions), plan for repeat IV iron administrations at intervals determined by rate of iron depletion 2
• Frequency of repeat dosing depends on monitoring labs every 2-3 months initially 2
• Consider soluble transferrin receptor (sTfR) if inflammation is present and ferritin becomes unreliable 2, 4